Misonix Receives Health Canada Approval for neXus
04 Marzo 2021 - 8:25AM
Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a
provider of minimally invasive therapeutic ultrasonic medical
devices and regenerative products that enhance clinical outcomes,
today announced that it has received a Health Canada license for
the neXus® Ultrasonic Surgical System. This approval confirms
that neXus meets the requirements of Health Canada, allowing
Misonix to commercialize neXus, along with its various handpieces
and disposable products, across Canada.
Stavros Vizirgianakis, President and Chief
Executive Officer of Misonix stated, “We are very pleased Health
Canada has approved the use of neXus. This approval, along with our
CE Mark certification, is further affirmation of our technology,
and allows us to continue expanding our installed base for neXus
outside the US. NeXus has seen very strong acceptance with
healthcare practitioners domestically since its soft launch in late
2019, and we are confident that it will have similar success in
markets such as Canada, where quality of care and patient outcomes
are the primary focus of healthcare providers.
“NeXus is a powerful, highly-integrated and
easy-to-use system incorporating the latest advances in ultrasonic
technology for increased efficiency and efficacy in treating
procedures across spine surgery, neurosurgery, orthopedic surgery,
laparoscopic surgery, and wound care. As we bring to market
additional state-of-the-art ultrasonic handpieces and disposable
offerings that leverage the neXus platform, we remain confident in
our ability to strengthen and expand our leadership position in
ultrasonic technology and to further diversify and grow our
revenues.”
Nexus is also registered and available for sale
in the EU, as well as a number of other select countries in Latin
America, Middle East, and Asia Pacific, including Australia and New
Zealand.
About Misonix, Inc.
Misonix, Inc. (Nasdaq: MSON) is a provider of
minimally invasive therapeutic ultrasonic medical devices and
regenerative tissue products. Its surgical team markets and sells
BoneScalpel and SonaStar, which facilitate precise bone sculpting
and removal of soft and hard tumors and tissue, primarily in the
areas of neurosurgery, orthopedic, plastic and maxillo-facial
surgery. The Company's wound team markets and sells TheraSkin,
Therion, TheraGenesis and SonicOne to debride, treat and heal
chronic and traumatic wounds in inpatient, outpatient and physician
office sites of service. At Misonix, Better Matters! That is why
throughout the Company’s history, Misonix has maintained its
commitment to medical technology innovation and the development of
products that radically improve outcomes for patients. Additional
information is available on the Company's web site at
www.misonix.com.
Contact: |
|
Joe Dwyer |
Norberto Aja, Jennifer Neuman |
Chief Financial Officer |
JCIR |
Misonix, Inc. |
212-835-8500 or mson@jcir.com |
631-927-9113 |
|
Misonix (NASDAQ:MSON)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Misonix (NASDAQ:MSON)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024